Rimegepant: Acute Treatment for Migraine Headaches

References

• World Health Organization . Headache disorders. (2016). who.int/news-room/fact-sheets/detail/headache-disorders
   Google Scholar
• Burch R , RizzoliP , LoderE. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache58, 496–505 (2018).
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and injury incidence and prevalence collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet390, 1211–1259 (2017).
   PubMed Web of Science ®Google Scholar
• Lipton RB , CroopR , StockEGet al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J. Med.381, 142–149 (2019).
   PubMed Web of Science ®Google Scholar
• Bonafede M , SapraS , ShahNet al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache58, 700–714 (2018).
   PubMed Web of Science ®Google Scholar
• Giamberardino MA , AffaitatiG , CostantiniRet al. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J. Pain Res.10, 2751–2760 (2017).
   PubMed Web of Science ®Google Scholar
• Headache Classification of the International Headache Society . The international classification of headache disorders, 3rd edition (beta version). Cephalalgia33, 627–808 (2013).
   PubMed Web of Science ®Google Scholar
• International Headache Society (IHS) . Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia38, 1–211 (2018).
   Web of Science ®Google Scholar
• Kelman L . The triggers or precipitants of the acute migraine attack. Cephalalgia27(5), 394 (2007).
   PubMed Web of Science ®Google Scholar
• Wrobel Goldberg S , SilbersteinSD. Targeting CGRP: a new era for migraine treatment. CNS Drugs29, 443–452 (2015).
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG , MermodJJ , AmaraSGet al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. Nature304, 129–135 (1983).
   PubMed Web of Science ®Google Scholar
• Edvinsson L , HaanesKA , WarfvingeK , KrauseDN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat. Rev. Neurol.14, 338–350 (2018).
   PubMed Web of Science ®Google Scholar
• Karsan N , GoadsbyPJ. Calcitonin gene-related peptide and migraine. Curr. Opin. Neurol.28, 250–254 (2015).
   PubMed Web of Science ®Google Scholar
• Eftekhari S , SalvatoreCA , JohanssonS , ChenTB , ZengZ , EdvinssonL. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Res.1600, 93–109 (2015).
   PubMed Web of Science ®Google Scholar
• Eftekhari S , WarfvingeK , BlixtFW , EdvinssonL. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J. Headache Pain14, 1289–1303 (2013).
   Web of Science ®Google Scholar
• Mulderry PK , GhateiMA , SpokesRAet al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience25, 195–205 (1988).
   PubMed Web of Science ®Google Scholar
• Marvizón JC , PérezOA , SongBet al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience148, 250–265 (2007).
   PubMed Web of Science ®Google Scholar
• Oku R , SatohM , FujiiN , OtakaA , YajimaH , TakagiH. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res.403, 350–354 (1987).
   PubMed Web of Science ®Google Scholar
• Russell FA , KingR , SmillieS-J , KodjiX. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev.94, 1099–1142 (2014).
   PubMed Web of Science ®Google Scholar
• Bernstein C , BursteinR. Sensitization of the trigeminovascular path-way: perspective and implications to migraine pathophysiology. J. Clin. Neurol.8, 89–99 (2012).
   PubMed Web of Science ®Google Scholar
• Recober A , KaiserEA , KuburasA , RussoAF. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology58, 156–165 (2010).
   PubMed Web of Science ®Google Scholar
• Recober A , KuburasA , ZhangZ , WemmieJA , AndersonMG , RussoAF. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J. Neurosci.29, 8798–8804 (2009).
   PubMed Web of Science ®Google Scholar
• Mulderry PK , GhateiMA , BishopAE , AllenYS , PolakJM , BloomSR. Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul. Pept.12, 133–143 (1985).
   PubMedGoogle Scholar
• Lipton RB , MunjalS , BuseDCet al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study. Headache57, 1026–1040 (2017).
   PubMed Web of Science ®Google Scholar
• Perry CM , MarkhamA. Sumatriptan: an updated review of its use in migraine. Drugs55, 889–922 (1998).
   PubMed Web of Science ®Google Scholar
• Cortelli P , AllaisG , TulloVet al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol. Sci.32(Suppl. 1), S95–S98 (2011).
   PubMed Web of Science ®Google Scholar
• Géraud G , KeywoodC , SenardJM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache43, 376–388 (2003).
   PubMed Web of Science ®Google Scholar
• Derry CJ , DerryS , MooreRA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst. Rev.2, CD008615 (2012).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , HollandS , FreitagFet al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology78, 1337–1345b (2012).
   PubMed Web of Science ®Google Scholar
• American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache59, 1–18 (2019).
   Web of Science ®Google Scholar
• Nurtec ODT (rimegepant), prescribing information. Biohaven Pharmaceuticals Inc, CT, USA (2020).
   Google Scholar
• Croop R , GoadsbyPJ , StockDAet al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, Phase III, double-blind, placebo-controlled trial. Lancet394, 737–745 (2019).
   PubMed Web of Science ®Google Scholar
• Lipton RB , ConwayCM , StockEGet al. Efficacy, safety, and tolerability of rimegepant 75mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a Phase III, double-blind, randomized, placebo-controlled trial, study 301. Presented at: American Headache Society 60th Annual Scientific MeetingCA, USA (2018).
   Google Scholar
• Conway CM , DubowchikGM , CroopR , CoricV. Phase I and II safety, tolerability and pharmacokinetics of single and multiple dose rimegepant as compared to the predicted clinically efficacious dose range. Presented at: American Headache Society 61st Annual Scientific MeetingPA, USA (2019).
   Google Scholar
• Tong G , SavantI , JariwalaNet al. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. J. Headache Pain14(Suppl. 1), P118 (2013).
   Web of Science ®Google Scholar
• Marcus R , GoadsbyPJ , DodickD , SockD , ManosG , FischerTZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia34(2), 114–125 (2014).
   PubMed Web of Science ®Google Scholar
• Croop R , BermanG , KudrowDet al. Long-term safety of rimegepant 75mg for the acute treatment of migraine. Presented at: American Academy of Neurology Annual Meeting (2020) ( Virtual).
   Google Scholar
• Moreno-Ajona D , Pérez-RodríguezA , GoadsbyPJ. Gepants, calcitonin gene-related peptide receptor antagonists: what could be their role in migraine treatment?Curr. Opin. Neurol.33, 309–315 (2020).
   PubMed Web of Science ®Google Scholar
• Mullin K , KudrowD , CroopRet al. Potential for treatment benefit of small molecule CGRP receptor antagonists plus monoclonal antibody in migraine therapy. Neurology94, e2121–e2125 (2020).
   PubMed Web of Science ®Google Scholar
• Luo G , ChenL , ConwayCMet al. Discovery of (5S, 6S, 9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyri din-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J. Med. Chem.55, 10644–10651 (2012).
   PubMed Web of Science ®Google Scholar
• Shi L , LehtoSG , ZhuDXet al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J. Pharmacol. Exp. Ther.356, 223–231 (2016).
   PubMed Web of Science ®Google Scholar